Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

William Jonas (NPI 1962443051)

Field	Value
Entity Type	Individual
Organization	William Jonas
Address	1800 Howell Mill Rd Nw Ste 800
City	Atlanta
State	GA
ZIP	30318
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 9, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider’s billed activity is overwhelmingly Medicare-facing: total Medicare revenue is $1.8M and there is no Medicaid billing on file, making the practice effectively single-payer for publicly billed care. The NPI was enumerated on 2006-06-09 (~20 years ago), indicating an established billing history in the Medicare program.

Revenue is highly concentrated in a small set of biologic drug administrations: the precomputed top 3 Medicare codes account for 73.4% of this provider’s total Medicare revenue, driven by J9299 (38.9%), J9271 (27.2%), and J0897 (7.3%). This concentration signals that a few high-cost oncology drugs dominate the practice’s Medicare receipts.

The code mix is consistent with an oncology infusion practice focused on immune checkpoint inhibitors and supportive bone-targeted therapy: J9299 (injection, nivolumab), J9271 (injection, pembrolizumab) and J0897 (injection, denosumab) are the top revenue drivers, and multiple chemotherapy administration and add-on codes (96413, 96417, 96415, 96365, 96367) appear across the top-25 list. Together these codes indicate regular in-office IV/subcutaneous antineoplastic drug delivery and supportive oncology care rather than a primary focus on unrelated outpatient specialties.

Competitive standing is mixed across products: for J9299 the provider ranks #71 of 505 nationally (86th percentile; typical, unremarkable volume for this code), while for J9271 the provider ranks #930 of 1841 (49th percentile; typical, unremarkable volume). By contrast, the provider is comparatively prominent for the biosimilar rituximab line Q5123, ranking #6 of 40 nationally (87th percentile; typical, unremarkable volume for this code), indicating niche leadership on that specific biosimilar despite otherwise typical national volumes for other top drugs.

Billing patterns show heavy utilization by claim count of lower-paid-per-unit drug billing: J9299 appears with 31.1K claims at $23 avg paid/claim for $715.8K revenue, J9271 has 12.2K claims at $41 avg paid/claim for $500.2K revenue, and J0897 shows 7.4K claims at $18 avg paid/claim for $133.9K revenue. These figures suggest a high-frequency drug administration model where volume, not per-claim price, drives large revenue contributions.

Evaluation & management coding is unusually active for certain visit levels: 99213 generated $69K (3.8% of Medicare revenue) and ranks #5146 of 457151 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code), while 99204 ranks #13824 of 227068 providers (94th percentile; notably above typical national volume for this code). This combination suggests above-average office visit intensity or a high established-patient throughput alongside infusion services.

Infusion and supportive service indicators are present and consistent with ambulatory chemotherapy operations: 96413 (506 claims, $51.1K revenue) ranks #669 of 7514 (91th percentile; typical, unremarkable volume for this code) and G0498 (78 claims, $13.7K revenue) ranks #174 of 896 (80th percentile; typical, unremarkable volume for this code), reflecting both standard infusion administration and occasional portable pump/home-continuation workflows. Multiple add-on infusion codes (96417, 96415, 96411) and related IV administration codes further support an on-site chemotherapy delivery model.

From a business-risk and positioning perspective, the provider’s dependence on Medicare ($1.8M) with no Medicaid revenue and a revenue profile concentrated in a few high-cost oncology drugs creates exposure to payer-specific reimbursement changes or shifts in drug utilization. The provider’s long tenure (NPI enumerated 2006-06-09, ~20 years ago) suggests an established operational footprint that likely supports the observed high-volume injectable drug and E/M activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	31,120	$20	$715.8K
J9271	Injection, pembrolizumab, 1 mg	12,200	$40	$500.2K
J0897	Injection, denosumab, 1 mg	7,440	$20	$133.9K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	3,410	$30	$112.6K
J1437	Injection, ferric derisomaltose, 10 mg	6,900	$20	$110.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,100	$60	$69K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	510	$100	$51.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	390	$90	$35.5K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	140	$120	$16.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	50	$320	$15.1K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

William Jonas — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	28	40	15,200	$40	$767.3K
J9299	1	10	15,910	$20	$431.3K
Q5123	2	10	3,410	$30	$120.5K
J0897	49	290	2,460	$20	$90.2K
J1437	3	30	2,850	$20	$56.4K
J1454	16	20	80	$330	$25.9K
96413	16	160	170	$90	$20.3K
J3490	27	50	50	$320	$19.8K
99214	2,277	13,640	120	$80	$17.8K
99233	3,520	3,880	90	$90	$13.9K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with William Jonas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Vasileios Assikis	GA	Hematology & Oncology Physician	$3M	$0
Jonathan Bender	GA	Hematology & Oncology Physician	$2.6M	$0
Minesh Patel	GA	Hematology & Oncology Physician	$2.4M	$0
Vipin Ramprasad Lohiya	GA	Hematology & Oncology Physician	$2.3M	$0
Trevor Feinstein	GA	Hematology & Oncology Physician	$1.4M	$0
Jay Rhee	GA	Hematology & Oncology Physician	$871.7K	$0
Nikita Amin	GA	Hematology & Oncology Physician	$444.2K	$0

Nearby Providers

Other providers in the same ZIP code as William Jonas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Total Renal Care Inc	GA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$7.3M
Labsolutions LLC	GA	Clinical Medical Laboratory	$0	$1.8M
Morehouse Healthcare, Inc.	GA	Cardiovascular Disease Physician	$0	$1.3M
Terry Walton	GA	Clinical Social Worker	$447.2K	$0
Holton Dialysis Clinic, LLC	GA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$332.7K
Bruce Bode	GA	Endocrinology, Diabetes & Metabolism Physician	$327.9K	$0
David Robertson	GA	Endocrinology, Diabetes & Metabolism Physician	$294.4K	$0
Jonathan Ownby	GA	Endocrinology, Diabetes & Metabolism Physician	$218.6K	$0
Nazia Bandukwala	GA	Urology Physician	$194.5K	$0
Spencer Kozinn	GA	Urology Physician	$172.5K	$0

William Jonas — Billing Profile & Reimbursement Data

Sign up for William Jonas — Billing Profile & Reimbursement Data policy alerts

William Jonas — Billing Profile & Reimbursement Data

Sign up for William Jonas — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References